|
A phase 2 study of galunisertib (TGF-Β R1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC). |
|
|
Consulting or Advisory Role - Bayer (Inst) |
Research Funding - Agios; Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Tekmira (Inst) |
|
|
Research Funding - Lilly (Inst) |
|
|
Research Funding - Lilly (Inst) |
|
|
Research Funding - Lilly (Inst) |
|
|
Honoraria - Bayer Schering Pharma; Bristol-Myers Squibb; Lilly; Sillajen; Sirtex Medical |
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Lilly; MSD; Sirtex Medical |
Speakers' Bureau - Bayer Schering Pharma; Lilly |
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical |
|
|
Research Funding - Lilly (Inst) |
|
Isabelle Ollivier-Hourmand |
Research Funding - Lilly (Inst) |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Lilly |
Travel, Accommodations, Expenses - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Lilly |
Travel, Accommodations, Expenses - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Lilly |
Travel, Accommodations, Expenses - Lilly |
|
|
Research Funding - Lilly (Inst) |
|
|
No Relationships to Disclose |
|
|
Research Funding - Lilly (Inst) |